138 related articles for article (PubMed ID: 30340917)
1. Relationship between allostatic load and clinical outcomes in youth at ultra-high risk for psychosis in the NEURAPRO study.
Berger M; Lavoie S; McGorry PD; Nelson B; Markulev C; Yuen HP; Schaefer M; Sarnyai Z; Amminger GP
Schizophr Res; 2020 Dec; 226():38-43. PubMed ID: 30340917
[TBL] [Abstract][Full Text] [Related]
2. Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial.
Bolt LK; Amminger GP; Farhall J; McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EYH; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Allott KA
Schizophr Res; 2019 Apr; 206():67-74. PubMed ID: 30558978
[TBL] [Abstract][Full Text] [Related]
3. Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial.
Berger M; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EYH; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Mitchell TW; Meyer BJ; Thompson A; Yung AR; McGorry PD; Amminger GP
Front Psychiatry; 2019; 10():393. PubMed ID: 31244693
[No Abstract] [Full Text] [Related]
4. Allostatic load is associated with psychotic symptoms and decreases with antipsychotic treatment in patients with schizophrenia and first-episode psychosis.
Berger M; Juster RP; Westphal S; Amminger GP; Bogerts B; Schiltz K; Bahn S; Steiner J; Sarnyai Z
Psychoneuroendocrinology; 2018 Apr; 90():35-42. PubMed ID: 29427955
[TBL] [Abstract][Full Text] [Related]
5. NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders.
Markulev C; McGorry PD; Nelson B; Yuen HP; Schaefer M; Yung AR; Thompson A; Berger G; Mossaheb N; Schlögelhofer M; Smesny S; de Haan L; Riecher-Rössler A; Nordentoft M; Chen EYH; Verma S; Hickie I; Amminger GP
Early Interv Psychiatry; 2017 Oct; 11(5):418-428. PubMed ID: 26279065
[TBL] [Abstract][Full Text] [Related]
6. The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis.
Amminger GP; Nelson B; Markulev C; Yuen HP; Schäfer MR; Berger M; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EYH; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; McGorry PD
Biol Psychiatry; 2020 Feb; 87(3):243-252. PubMed ID: 31690495
[TBL] [Abstract][Full Text] [Related]
7. Frontal delta power associated with negative symptoms in ultra-high risk individuals who transitioned to psychosis.
Lavoie S; Schäfer MR; Whitford TJ; Benninger F; Feucht M; Klier CM; Yuen HP; Pantelis C; McGorry PD; Amminger GP
Schizophr Res; 2012 Jul; 138(2-3):206-11. PubMed ID: 22520856
[TBL] [Abstract][Full Text] [Related]
8. The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trial.
Susai SR; Mongan D; Healy C; Cannon M; Nelson B; Markulev C; Schäfer MR; Berger M; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EYH; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; McGorry PD; Föcking M; Cotter D; Amminger GP
Brain Behav Immun; 2022 Jan; 99():147-156. PubMed ID: 34624483
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal Cognitive Changes in Young Individuals at Ultrahigh Risk for Psychosis.
Lam M; Lee J; Rapisarda A; See YM; Yang Z; Lee SA; Abdul-Rashid NA; Kraus M; Subramaniam M; Chong SA; Keefe RSE
JAMA Psychiatry; 2018 Sep; 75(9):929-939. PubMed ID: 30046827
[TBL] [Abstract][Full Text] [Related]
10. Erythrocyte membrane fatty acid concentrations and myelin integrity in young people at ultra-high risk of psychosis.
Collins M; Bartholomeusz C; Mei C; Kerr M; Spark J; Wallis N; Polari A; Baird S; Buccilli K; Dempsey SA; Ferguson N; Formica M; Krcmar M; Quinn AL; Wannan C; Oldham S; Fornito A; Mebrahtu Y; Ruslins A; Street R; Loschiavo K; McGorry PD; Nelson B; Amminger GP
Psychiatry Res; 2024 Jul; 337():115966. PubMed ID: 38810536
[TBL] [Abstract][Full Text] [Related]
11. Frontal slow wave resting EEG power is higher in individuals at Ultra High Risk for psychosis than in healthy controls but is not associated with negative symptoms or functioning.
Sollychin M; Jack BN; Polari A; Ando A; Amminger GP; Markulev C; McGorry PD; Nelson B; Whitford TJ; Yuen HP; Lavoie S
Schizophr Res; 2019 Jun; 208():293-299. PubMed ID: 30738699
[TBL] [Abstract][Full Text] [Related]
12. Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis.
Alqarni A; Mitchell TW; McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Berger M; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EYH; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Meyer BJ; Amminger GP
Schizophr Res; 2020 Dec; 226():52-60. PubMed ID: 31606244
[TBL] [Abstract][Full Text] [Related]
13. Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis.
Lo Cascio N; Saba R; Hauser M; Vernal DL; Al-Jadiri A; Borenstein Y; Sheridan EM; Kishimoto T; Armando M; Vicari S; Fiori Nastro P; Girardi P; Gebhardt E; Kane JM; Auther A; Carrión RE; Cornblatt BA; Schimmelmann BG; Schultze-Lutter F; Correll CU
Eur Child Adolesc Psychiatry; 2016 Oct; 25(10):1091-102. PubMed ID: 26921232
[TBL] [Abstract][Full Text] [Related]
14. Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids.
Amminger GP; Mechelli A; Rice S; Kim SW; Klier CM; McNamara RK; Berk M; McGorry PD; Schäfer MR
Transl Psychiatry; 2015 Jan; 5(1):e495. PubMed ID: 25585167
[TBL] [Abstract][Full Text] [Related]
15. Predictors of remission from the ultra-high risk state for psychosis.
Glenthøj LB; Kristensen TD; Wenneberg C; Hjorthøj C; Nordentoft M
Early Interv Psychiatry; 2021 Feb; 15(1):104-112. PubMed ID: 31910496
[TBL] [Abstract][Full Text] [Related]
16. The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quo.
McHugh MJ; McGorry PD; Yuen HP; Hickie IB; Thompson A; de Haan L; Mossaheb N; Smesny S; Lin A; Markulev C; Schloegelhofer M; Wood SJ; Nieman D; Hartmann JA; Nordentoft M; Schäfer M; Amminger GP; Yung A; Nelson B
Schizophr Res; 2018 May; 195():543-548. PubMed ID: 29055567
[TBL] [Abstract][Full Text] [Related]
17. Childhood maltreatment and transition to psychotic disorder independently predict long-term functioning in young people at ultra-high risk for psychosis.
Yung AR; Cotter J; Wood SJ; McGorry P; Thompson AD; Nelson B; Lin A
Psychol Med; 2015 Dec; 45(16):3453-65. PubMed ID: 26166153
[TBL] [Abstract][Full Text] [Related]
18. Prediction of clinical outcomes beyond psychosis in the ultra-high risk for psychosis population.
Polari A; Yuen HP; Amminger P; Berger G; Chen E; deHaan L; Hartmann J; Markulev C; McGorry P; Nieman D; Nordentoft M; Riecher-Rössler A; Smesny S; Stratford J; Verma S; Yung A; Lavoie S; Nelson B
Early Interv Psychiatry; 2021 Jun; 15(3):642-651. PubMed ID: 32558302
[TBL] [Abstract][Full Text] [Related]
19. Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis.
Velthorst E; Nieman DH; Becker HE; van de Fliert R; Dingemans PM; Klaassen R; de Haan L; van Amelsvoort T; Linszen DH
Schizophr Res; 2009 Apr; 109(1-3):60-5. PubMed ID: 19272756
[TBL] [Abstract][Full Text] [Related]
20. Basic symptoms in young people at ultra-high risk of psychosis: Association with clinical characteristics and outcomes.
Youn S; Phillips LJ; Amminger GP; Berger G; Chen EYH; de Haan L; Hartmann JA; Hickie IB; Lavoie S; Markulev C; McGorry PD; Mossaheb N; Nieman DH; Nordentoft M; Riecher-Rössler A; Schäfer MR; Schlögelhofer M; Smesny S; Thompson A; Verma S; Yuen HP; Yung AR; Nelson B
Schizophr Res; 2020 Feb; 216():255-261. PubMed ID: 31866077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
